Grace Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Grace Therapeutics completed a private placement on August 4, 2026, issuing 4,761,904 shares of common stock at $2.10 per share for ~$10 million gross proceeds (before placement agent fees). Closing expected August 6, 2026. Net proceeds intended to fund GTx-104 manufacturing and regulatory work; company expects cash runway extended to end of calendar 2028. Company also announced dual-source manufacturing strategy with technology transfer to second U.S. contract manufacturer underway.
Why this rating
~$10M financing is ~29% of $35.1M market cap—material for runway extension but typical biotech capital raise at pre-commercial stage. No transformational asset, product, or partnership announced; routine financing for clinical-stage company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.